Published in J Neurol Neurosurg on January 01, 2014
Unresectable Recurrent Multiple Meningioma: A Case Report with Radiological Response to Somatostatin Analogues. Case Rep Oncol (2016) 0.75
Genetic variants and increased risk of meningioma: an updated meta-analysis. Onco Targets Ther (2017) 0.75
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 10.71
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol (2007) 8.07
Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell (2003) 5.66
Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet (1995) 4.46
Epidemiology and etiology of meningioma. J Neurooncol (2010) 3.64
Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol (2006) 3.33
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet (2013) 3.19
Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol (2009) 2.06
Pathological classification and molecular genetics of meningiomas. J Neurooncol (2010) 2.03
Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res (1997) 1.83
Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. J Biol Chem (1998) 1.54
Molecular pathogenesis of meningiomas. J Neurooncol (2004) 1.42
Review of meningioma histopathology. Neurosurg Focus (2007) 1.38
The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. Oncogene (2003) 1.38
Impaired survival and long-term neurological problems in benign meningioma. Neuro Oncol (2012) 1.37
Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer (2005) 1.36
Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res (2005) 1.33
The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus (2011) 1.33
Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol (1995) 1.32
Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol (2001) 1.27
The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia (2008) 1.23
Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet (2002) 1.22
Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res (1999) 1.15
Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg (1992) 1.14
Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther (2004) 1.11
Genomic landscape of meningiomas. Brain Pathol (2009) 1.08
Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol (2004) 1.06
Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. Neoplasia (2011) 1.02
Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms. Int J Cancer (2003) 1.02
PI3Kinase signaling in glioblastoma. J Neurooncol (2010) 1.01
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol (2012) 1.00
Update on meningiomas. Oncologist (2011) 0.99
Targeted disruption of the Mn1 oncogene results in severe defects in development of membranous bones of the cranial skeleton. Mol Cell Biol (2005) 0.98
The importance of pial blood supply to the development of peritumoral brain edema in meningiomas. J Neurosurg (1997) 0.95
Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations. J Neurosci Res (1999) 0.92
Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. Vet Pathol (2009) 0.92
Aberrant signaling pathways in meningiomas. J Neurooncol (2010) 0.91
Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors. FEBS J (2009) 0.86
Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Radiat Oncol (2010) 0.86
The significance of immunohistochemical expression of merlin, Ki-67, and p53 in meningiomas. Appl Immunohistochem Mol Morphol (2014) 0.85
Analysis of the PTEN gene in human meningiomas. Neuropathol Appl Neurobiol (1998) 0.83
Molecular analysis of alterations of the p18INK4c gene in human meningiomas. Neuropathol Appl Neurobiol (2000) 0.82
The oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma. Arch Pathol Lab Med (2011) 0.81
Association between mutation of the NF2 gene and monosomy 22 in menopausal women with sporadic meningiomas. BMC Med Genet (2013) 0.79
Current Studies of Immunotherapy on Glioblastoma. J Neurol Neurosurg (2014) 0.75